ImmunOs Therapeutics
PrivateLast Round
Series C
Sep 17, 2024
Total Funding Raised
$100.2M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ImmunOs Therapeutics operates in Healthcare & Life Sciences and is based in Schlieren. Its latest recorded funding round was a Series C round in September 2024.
ImmunOs Therapeutics is a biotechnology company that develops novel human immunomodulatory proteins and biologic therapies for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunOs Therapeutics Comparables
Compare ImmunOs Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immune-Onc Therapeutics | 83% | |
| KAHR Medical | 82% | |
| Biond Biologics | 78% |
For institutional investors. Book with your work email.
ImmunOs Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 17, 2024 | ||||
| Series B | Jun 7, 2022 | ||||
| Series A | Dec 10, 2019 | ||||
| Series A | Sep 18, 2018 |
For institutional investors. Book with your work email.
ImmunOs Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Series A, Series B, Series C |
| GL Capital Group | Series B |
| Gimv | Series B, Series C |
| PEAK6 Strategic Capital | Series B |
| Fiscus DAO | Series B |
| PEAK6 Investments | Series B |
| BioInnovation Capital | Series B, Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 49% MoM.
- Jul 29, 2026
Monthly visitors increased 85% MoM.
For institutional investors. Book with your work email.
ImmunOs Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ImmunOs Therapeutics's valuation, stock price, and market status.
Is ImmunOs Therapeutics a public or private company?
ImmunOs Therapeutics is a private company.
What is the current stock price of ImmunOs Therapeutics?
ImmunOs Therapeutics is a private company, so its shares have no public market price. Caplight tracks ImmunOs Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ImmunOs Therapeutics worth (valuation)?
Valuation information for ImmunOs Therapeutics is not publicly available.
Can I buy ImmunOs Therapeutics stock?
ImmunOs Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ImmunOs Therapeutics's last funding round?
ImmunOs Therapeutics's most recent funding round was Series C on September 17, 2024.
Who are the main investors in ImmunOs Therapeutics?
Key investors in ImmunOs Therapeutics include BioMedPartners, Gimv, BioInnovation Capital, Pfizer Ventures, Mission BioCapital.
Will ImmunOs Therapeutics IPO soon?
No public IPO plans have been announced for ImmunOs Therapeutics.
How can I track ImmunOs Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in ImmunOs Therapeutics's shares on secondary markets.